Tardiva risposta completa dopo lunga remissione da trattamento con schedula FOLFIRI-aflibercept per cancro colorettale metastatico dopo progressione a schedula folfox-bevacizumab

Translated title of the contribution: Late complete response after long remission from treatment with FOLFIRI-aflibercept for metastatic colorectal cancer after progression to FOLFOX-bevacizumab

Chiara De Divitiis, Antonino Cassata, Guglielmo Nasti, Alessandro Ottaiano, Anna Nappi, Maria Luisa Barretta, Rosario Vincenzo Iaffaioli

Research output: Contribution to journalArticlepeer-review

Abstract

We report a case of a 59 years old man affected by an adenocarcinoma of the rectum RAS wild type with synchronous liver metastases, diagnosed on October, 2011. The patient underwent a left hemicolectomy with left hepatic lobectomy. In view of the recurrence of the disease from 18.01.2012 to 13.7.2012 we practiced first line chemotherapy with FOLFOX plus bevacizumab for 12 total cycles, obtaining a complete response, so the patient underwent clinical follow-up controls that proved negative until January, 2013, when, following the appearance of pain in the pelvis to the left, a total body PET with 18FDG was performed that documented the presence of bone metastases (left hemipelvis), confirmed histologically. Therefore from 03.18.2013 to 29.03.2013 the patient underwent a left ischium radiotherapy (for a total of 30 Gy). On May, 2013, a CT scan showed a progression of disease in the liver and so the patient started a II line chemotherapy with FOLFIRI and aflibercept, treatment still ongoing. At 46 months after diagnosis, the patient is in good general condition, presenting a complete response of the disease, demonstrated by a total body CT scan, performed in April 2015, completely negative.

Translated title of the contributionLate complete response after long remission from treatment with FOLFIRI-aflibercept for metastatic colorectal cancer after progression to FOLFOX-bevacizumab
Original languageItalian
Pages (from-to)e407-e413
JournalRecenti Progressi in Medicina
Volume106
Issue number8
Publication statusPublished - Aug 1 2015

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Late complete response after long remission from treatment with FOLFIRI-aflibercept for metastatic colorectal cancer after progression to FOLFOX-bevacizumab'. Together they form a unique fingerprint.

Cite this